FTI Consulting, a life science and healthcare communications practice, has named Andrew Ward as its new managing director, it was reported on Friday.
Ward joins the group from the Financial Times, where he was the pharmaceuticals correspondent for almost three years, covering the business, finance, science and regulation of the global pharmaceuticals and medical equipment industries. In the new role, Ward will be expected to broaden and deepen FTI Consulting's client base globally.
Ben Atwell, senior managing director and global head of life sciences and healthcare at FTI Consulting, said: "Andrew was one of the sector's most respected reporters during his time covering healthcare, and brings invaluable global perspective to our prestigious client base. We look forward to benefiting from his deep media experience and welcoming him to our global team of over 50 healthcare experts."
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business